

Olivier Adotevi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6100460/publications.pdf>

Version: 2024-02-01

82
papers

2,884
citations

185998

28
h-index

197535

49
g-index

86
all docs

86
docs citations

86
times ranked

4409
citing authors

#	ARTICLE	IF	CITATIONS
1	Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 435-444.	0.3	15
2	Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 260.	1.7	26
3	Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer. <i>BMC Cancer</i> , 2022, 22, 529.	1.1	11
4	Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells. <i>Cancers</i> , 2022, 14, 3168.	1.7	8
5	Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen. <i>Cancer Research</i> , 2022, 82, 2517-2519.	0.4	2
6	BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity. <i>EJHaem</i> , 2021, 2, 128-133.	0.4	0
7	Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice. <i>Quality of Life Research</i> , 2021, 30, 3255-3266.	1.5	12
8	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. <i>Blood Advances</i> , 2021, 5, 1540-1551.	2.5	35
9	Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus. <i>Oncogene</i> , 2021, 40, 3030-3046.	2.6	31
10	First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G. , 2021, 9, e001998.		30
11	Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. <i>BMC Immunology</i> , 2021, 22, 38.	0.9	7
12	Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. <i>European Journal of Cancer</i> , 2021, 150, 1-9.	1.3	23
13	Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 669992.	2.2	18
14	Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. , 2021, 9, e002256.		18
15	Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 142.	2.8	106
16	Inflammatory and immunological profile in COPD secondary to organic dust exposure. <i>Clinical Immunology</i> , 2021, 229, 108798.	1.4	3
17	Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies. <i>Cancers</i> , 2021, 13, 4893.	1.7	19
18	Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. <i>Haematologica</i> , 2021, 106, 3056-3066.	1.7	28

#	ARTICLE	IF	CITATIONS
19	Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	2
20	Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells. <i>Frontiers in Immunology</i> , 2021, 12, 812171.	2.2	3
21	Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer. <i>International Journal of Cancer</i> , 2020, 147, 1199-1205.	2.3	10
22	A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 588-597.	3.2	42
23	Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6838.	1.8	21
24	Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. , 2020, 8, e001478.		22
25	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
26	Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. <i>Cells</i> , 2020, 9, 2071.	1.8	10
27	Characterization of chronic obstructive pulmonary disease in dairy farmers. <i>Environmental Research</i> , 2020, 188, 109847.	3.7	7
28	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , 2020, 34, 3228-3241.	3.3	27
29	Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 268-279.	1.6	31
30	Molecular description of ANGPT2 associated colorectal carcinoma. <i>International Journal of Cancer</i> , 2020, 147, 2007-2018.	2.3	15
31	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. <i>International Journal of Cancer</i> , 2019, 145, 3112-3125.	2.3	32
32	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 405-416.	2.9	63
33	Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC. <i>Lung Cancer</i> , 2019, 137, 23-30.	0.9	21
34	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2121.	2.2	35
35	High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4320-4331.	3.2	15
36	Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. <i>Onc Immunology</i> , 2019, 8, e1560919.	2.1	29

#	ARTICLE	IF	CITATIONS
37	Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1572-1577.	1.3	17
38	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	2.5	72
39	Circulating NKp46 ⁺ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer. <i>Oncolmmunology</i> , 2019, 8, e1527498.	2.1	28
40	CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells. <i>Cancer Research</i> , 2019, 79, 663-675.	0.4	62
41	Increased Levels of Interleukin-17A Exosomes in Psoriasis. <i>Acta Dermato-Venereologica</i> , 2019, 99, 1143-1147.	0.6	15
42	The Human Cytomegalovirus Strain DB Activates Oncogenic Pathways in Mammary Epithelial Cells. <i>EBioMedicine</i> , 2018, 30, 167-183.	2.7	53
43	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1433981.	2.1	167
44	In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. <i>Oncolmmunology</i> , 2018, 7, e1424673.	2.1	27
45	SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts. <i>Oncolmmunology</i> , 2018, 7, e1412030.	2.1	4
46	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. <i>International Journal of Cancer</i> , 2018, 143, 3008-3018.	2.3	16
47	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	5.1	108
48	Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy. <i>Human Gene Therapy</i> , 2018, 29, 1202-1212.	1.4	8
49	Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. <i>Oncotarget</i> , 2018, 9, 35394-35407.	0.8	6
50	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. <i>Oncotarget</i> , 2017, 8, 48959-48971.	0.8	5
51	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 ⁺ Th1 responses against telomerase in cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1137416.	2.1	21
52	IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. <i>Journal of Immunology</i> , 2016, 197, 85-96.	0.4	30
53	Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells. <i>Journal of Immunology</i> , 2016, 197, 1597-1608.	0.4	16
54	Metronomic cyclophosphamide therapy in hormone-naïve patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial. <i>Medical Oncology</i> , 2016, 33, 89.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score. <i>International Journal of Cancer</i> , 2016, 139, 2325-2335.	2.3	14
56	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. <i>Cancer Research</i> , 2016, 76, 4100-4112.	0.4	42
57	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. <i>Vaccines</i> , 2015, 3, 490-502.	2.1	43
58	CD20 alternative splicing isoform generates immunogenic <scp>CD</scp>4 helper <scp>T</scp> epitopes. <i>International Journal of Cancer</i> , 2015, 137, 116-126.	2.3	29
59	Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 603-612.	1.1	12
60	Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived from <i>Leishmania major</i> Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps toward Polytope Vaccine. <i>PLoS ONE</i> , 2014, 9, e108848.	1.1	28
61	Immunomodulatory Effects of Everolimus in a Long Responsive Patient With Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2014, 37, 51-54.	1.2	10
62	Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR-Based Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 28-36.	1.0	35
63	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1073-1077.	1.4	20
64	Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. <i>Oncolmmunology</i> , 2013, 2, e23430.	2.1	17
65	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. <i>Oncolmmunology</i> , 2012, 1, 326-333.	2.1	95
66	Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. <i>Oncolmmunology</i> , 2012, 1, 1617-1619.	2.1	11
67	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. <i>Clinical Cancer Research</i> , 2012, 18, 6284-6295.	3.2	54
68	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. <i>Clinical Cancer Research</i> , 2012, 18, 2943-2953.	3.2	97
69	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. <i>Blood</i> , 2011, 118, 4853-4862.	0.6	144
70	A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 991-998.	1.2	188
71	Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. <i>Blood</i> , 2010, 115, 3025-3032.	0.6	30
72	The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen. <i>Journal of Immunology</i> , 2010, 185, 418-423.	0.4	30

#	ARTICLE	IF	CITATIONS
73	Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice. <i>Vaccine</i> , 2010, 28, 6374-6381.	1.7	10
74	IMMUNOTHÉRAPIE DES CANCERS. <i>Bulletin De L'Academie Veterinaire De France</i> , 2009, , 363.	0.0	0
75	Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients. <i>Journal of Immunology</i> , 2008, 181, 431-439.	0.4	37
76	Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2008, 31, 101-112.	1.2	65
77	Lentiviral Vectors Encoding HIV-1 Polyepitopes Induce Broad CTL Responses In Vivo. <i>Molecular Therapy</i> , 2007, 15, 1203-1210.	3.7	57
78	B Subunit of Shiga Toxin-Based Vaccines Synergize with β -Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity. <i>Journal of Immunology</i> , 2007, 179, 3371-3379.	0.4	55
79	The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. <i>European Journal of Immunology</i> , 2006, 36, 1124-1135.	1.6	80
80	Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses. <i>Clinical Cancer Research</i> , 2006, 12, 3158-3167.	3.2	44
81	Immunogenic HLA-B7-restricted peptides of hTERT. <i>International Immunology</i> , 2006, 18, 1707-1718.	1.8	20
82	The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens. <i>Journal of Immunology</i> , 2000, 165, 3301-3308.	0.4	132